Autres langues Quince Therapeutics, Inc.

Actions

QNCX

US22053A1079

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,9851 ^USD	+2,61%		-7,07%	-6,18%

01/04	Quince Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
26/03	Transcript : Quince Therapeutics, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	01/04
North American Morning Briefing : Markets Steady -2-	26/03
Quince Therapeutics Launches Scientific Advisory Board	22/02
Quince Therapeutics, Inc. Launches Scientific Advisory Board	22/02
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	15/02
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	15/02
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Quince Therapeutics to Participate at Investor Events in January 2024	04/01
North American Morning Briefing : All Eyes on -2-	21/11
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Quince Therapeutics : Investor Presentation – November 2023	06/11
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	26/10/23
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23/10/23
Quince Therapeutics Completes Acquisition of EryDel S.p.A.	23/10/23
Quince Therapeutics, Inc. acquired EryDel S.p.A	23/10/23
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	28/09/23
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold	28/09/23
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia	28/09/23
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	28/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Quince Therapeutics, Inc.

Actions

QNCX

US22053A1079

Autres langues

Filtres